Fullcircle Wealth LLC Invests $209,000 in Gilead Sciences, Inc. (NASDAQ:GILD)

Fullcircle Wealth LLC bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) in the 2nd quarter, Holdings Channel reports. The firm bought 2,837 shares of the biopharmaceutical company’s stock, valued at approximately $209,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Private Wealth Management Group LLC bought a new position in shares of Gilead Sciences in the 4th quarter valued at about $29,000. CarsonAllaria Wealth Management Ltd. lifted its stake in Gilead Sciences by 198.3% in the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 238 shares during the last quarter. Sachetta LLC bought a new position in Gilead Sciences during the fourth quarter worth about $30,000. Palisade Asset Management LLC acquired a new position in Gilead Sciences during the first quarter worth approximately $29,000. Finally, Gladius Capital Management LP acquired a new position in Gilead Sciences during the fourth quarter worth approximately $34,000. 83.67% of the stock is owned by institutional investors.

Insider Buying and Selling at Gilead Sciences

In other news, insider Johanna Mercier sold 5,490 shares of the company’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total transaction of $406,150.20. Following the completion of the sale, the insider now owns 114,979 shares of the company’s stock, valued at approximately $8,506,146.42. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, insider Johanna Mercier sold 5,490 shares of Gilead Sciences stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total value of $406,150.20. Following the transaction, the insider now owns 114,979 shares in the company, valued at approximately $8,506,146.42. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $68.63, for a total value of $137,260.00. Following the transaction, the insider now directly owns 96,380 shares of the company’s stock, valued at approximately $6,614,559.40. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Gilead Sciences Price Performance

Shares of GILD traded up $0.82 during trading hours on Friday, hitting $76.72. 6,847,053 shares of the company were exchanged, compared to its average volume of 7,242,981. The company has a quick ratio of 0.94, a current ratio of 1.08 and a debt-to-equity ratio of 1.31. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $87.86. The company has a market cap of $95.58 billion, a price-to-earnings ratio of 213.11, a P/E/G ratio of 3.37 and a beta of 0.18. The firm’s fifty day moving average is $71.87 and its 200 day moving average is $70.18.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 27th. Shareholders of record on Friday, September 13th will be paid a dividend of $0.77 per share. The ex-dividend date of this dividend is Friday, September 13th. This represents a $3.08 dividend on an annualized basis and a yield of 4.01%. Gilead Sciences’s payout ratio is 855.56%.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on GILD shares. StockNews.com upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, April 27th. Royal Bank of Canada increased their price objective on shares of Gilead Sciences from $71.00 to $72.00 and gave the company a “sector perform” rating in a research report on Friday, August 9th. Barclays reduced their target price on shares of Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating for the company in a report on Monday, April 29th. BMO Capital Markets increased their price target on shares of Gilead Sciences from $80.00 to $85.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Finally, Raymond James upgraded Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 price objective for the company in a report on Monday, July 8th. Twelve research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $81.94.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.